PV Bulletin

Changes to Labels and Patient Information Leaflets - Self-Certification Process

The MHRA has issued new guidance allowing Marketing Authorisation Holders to submit certain changes to labels and PILs through a streamlined self-certification process.

PV Impact Brief

Urgency: HighConfidence: high

What changed

Introduction of a self-certification process for labeling updates, allowing for quicker implementation of certain changes to labels and Patient Information Leaflets, unless those changes fall under categories P1-P4 which require a full assessment.

Why it matters

This regulatory update can reduce the time for Marketing Authorisation Holders (MAHs) to implement safety-related changes, thus enhancing patient safety and compliance.

Action needed

MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Annual review recommended for compliance updates.

Policy change details

Document type
Guideline
Policy status
final
Publication date
2026-07-03
Policy change
New supplementary guidance has been issued by the MHRA regarding the submission of changes to labels and Patient Information Leaflets (PILs) through the self-certification process.

Key changes

Provides additional procedural details and requirements for using the self-certification route for labelling and PIL updates, ensuring faster implementation of administrative and certain safety-related changes.

Affected workflows

Labeling

Responsible groups

Regulatory AffairsPharmacovigilanceSafety Operations

Document identifiers

Supplementary guidance self-certification

PV impact

MAHs can utilize this streamlined process for specific types of labelling updates, potentially reducing the time required to implement safety-related changes in the PIL and on packaging.

View regulator source

Source document details

Exact policy details

Default route for registering changes to labels and leaflets
Self-certification
Applies to: Applicable unless changes fall under categories P1-P4
Regulation 267 of the Human Medicines Regulations (2012) · p. 1 · High · Source
Timeframe for acceptance letter after self-certification submission
14 days
Applies to: After validation of submission
Submission decision tree section · p. 3 · High · Source
Timeline for expedited review for OTC medicines with PAGB
30 days
Applies to: When an optional submission has been made to PAGB
P2 category section · p. 2 · High · Source
Categories requiring full assessment instead of self-certification
P1-P4
Applies to: Proposed updates that fall into these categories
What changes fall into the P1-P4 categories section · p. 2 · High · Source
Supporting documents for self-certification
eCTD documentation
Applies to: Required for all self-certification submissions
How to submit – documentation required section · p. 4 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 3, 2026

Full briefing

Practical implication

MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

The new supplementary guidance from the MHRA outlines a self-certification process for submitting changes to labels and Patient Information Leaflets (PILs). This process is designed to enable faster implementation of administrative and specific safety-related changes, provided those changes do not fall into categories requiring full assessment.

What changed: Introduction of a self-certification process for labeling updates, allowing for quicker implementation of certain changes to labels and Patient Information Leaflets, unless those changes fall under categories P1-P4 which require a full assessment.

Why it matters: This regulatory update can reduce the time for Marketing Authorisation Holders (MAHs) to implement safety-related changes, thus enhancing patient safety and compliance.

Practical implication: MAHs must categorize their proposed label and PIL updates, utilizing the self-certification route for those not requiring full assessment; submissions validated through this route will receive acceptance letters within 14 days.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward